Rapid development of hypertension by sorafenib: Toxicity or target?

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 5947-5949

  Humphreys, Benjamin D ^a,b   Atkins, Michael B ^c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AXITINIB; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PACLITAXEL; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD PRESSURE MONITORING; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; METASTASIS; NONHUMAN; NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZENESULFONATES; BLOOD PRESSURE; DRUG DELIVERY SYSTEMS; DRUG DOSAGE CALCULATIONS; DRUG TOXICITY; HUMANS; HYPERTENSION; MICE; MODELS, BIOLOGICAL; NEOPLASMS; PYRIDINES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349685095     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1717     Document Type: Note

References (12)

1. Maitland ML, Kasza KE, Karrison T, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009;15:6250-6257
2. Horowitz JR, Rivard A, van der Zee R, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997;17:2793-2800
3. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130:691-703. (Pubitemid 47268059)
4. Schor-Bardach R, Alsop DC, Pedrosa I, et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 2009;251: 731-742
5. Steeghs N, Gelderblom H, Roodt JO, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008;14:3470-3476
6. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19:1955-1961
7. Fukumura D, Gohongi T, Kadambi A, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A 2001;98:2604-2609 (Pubitemid 32209529)
8. Franklin PH, Banfor PN, Tapang P, et al. Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4- yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition. J Pharmacol Exp Ther 2009;329:928-937, PubMed doi:10.1124/ jpet.108.144816.
9. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678
10. Kim JJ, Vaziri SA, Elson P, Rini BI, Ganapathi MK, Ganapathi R. VEGF single necleotide polymorphisms and correlation to sunitinib-induced hypertension in metastatic renal cell carcinoma patients. J Clin Oncol 2009;27:suppl: abstr 5005.
11. Rini BI, Schiller JH, Fruehauf JP, et al. Association of diastolic blood pressure (dBP)> 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). J Clin Oncol 2008; 26:suppl: abstr 3543.
12. Patel TV, Morgan JA, Demetri GD, et al. A preeclampsia- like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008;100:282-284